Earnings Call Summary | InspireMD(NSPR.US) Q2 2024 Earnings Conference
Earnings Call Summary | InspireMD(NSPR.US) Q2 2024 Earnings Conference
The following is a summary of the InspireMD, Inc. (NSPR) Q2 2024 Earnings Call Transcript:
以下是InspireMD,Inc.(NSPR)2024年第二季度業績會議通話記錄摘要:
Financial Performance:
金融業績:
InspireMD reported a quarterly revenue of $1.74 million, marking a growth of 5.4% from the same quarter last year.
Gross profit decreased by 32.6% to $331,000 due to increased material and labor costs, despite a slight increase in revenue.
Net loss for the quarter was $7,909,000, compared to a net loss of $5,077,000 in the second quarter of 2023.
InspireMD報告了174萬美元的季度營業收入,同比去年同期增長5.4%。
由於材料和勞動成本增加,毛利潤下降32.6%,儘管營業收入輕微增長。
本季度淨虧損爲790.9萬美元,2023年第二季度淨虧損爲507.7萬美元。
Business Progress:
業務進展:
InspireMD is preparing for the U.S. commercial launch of CGuard Prime, recruiting top talent and establishing a U.S. HQ in Southeast Florida.
The company presented positive one-year outcomes for the C-GUARDIANS clinical trial, supporting the efficacy of the CGuard Carotid Stent System.
They are anticipating FDA approval of CGuard Prime in the first half of 2025 and are preparing for significant commercial activities.
InspireMD正在爲CGuard Prime的美國商業推出做準備,招募頂尖人才,在美國東南部建立總部。
公司公佈了C-GUARDIANS臨床試驗一年的積極結果,支持CGuard頸動脈支架系統的功效。
他們預計CGuard Prime將於2025年上半年獲得FDA批准,併爲重要商業活動做準備。
Opportunities:
機會:
InspireMD's CGuard Carotid Stent System is set to potentially become the gold standard in carotid implants, bolstered by positive trial results and pending U.S. approval.
Expansion into the U.S. market could significantly increase revenue given the higher procedure rates and reimbursement levels compared to current markets.
InspireMD的CGuard頸動脈支架系統有望成爲頸動脈植入物的黃金標準,受到積極試驗結果和即將獲得的美國批准的支持。
進軍美國市場可能會顯著增加營業收入,因爲相比目前市場,美國市場的手術率和補償水平更高。
Risks:
風險:
The ongoing investment in clinical trials such as C-GUARDIANS II and III could increase operating expenses significantly, impacting financial stability.
持續投資於C-GUARDIANS II和III等臨床試驗可能會顯著增加營業費用,影響財務穩定性。
More details: InspireMD IR
更多詳細信息:InspireMD IR
Tips: This article is generated by AI. The accuracy of the content can not be fully guaranteed. For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示:本文由AI生成。文章內容的準確性無法完全保證。有關更全面的詳細信息,請參閱IR網站。本文只是爲投資者提供參考,沒有任何指導或推薦建議。